XML 75 R51.htm IDEA: XBRL DOCUMENT
v3.21.2

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Oct. 03, 2021 | Sep. 27, 2020 | Oct. 03, 2021 | Sep. 27, 2020
Sales by segment of business |  |  |  |
Sales to customers | $ 23,338 | $ 21,082 | $ 68,971 | $ 60,109
Percent Change (as a percent) | 10.70% |  | 14.70% |
U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 11,963 | 11,086 | $ 34,993 | 31,324
Percent Change (as a percent) | 7.90% |  | 11.70% |
International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 11,375 | 9,996 | $ 33,978 | 28,785
Percent Change (as a percent) | 13.80% |  | 18.00% |
Consumer Health |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,700 | 3,514 | $ 10,978 | 10,435
Percent Change (as a percent) | 5.30% |  | 5.20% |
Consumer Health | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,625 | 1,556 | $ 4,987 | 4,853
Percent Change (as a percent) | 4.50% |  | 2.80% |
Consumer Health | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,075 | 1,958 | $ 5,991 | 5,582
Percent Change (as a percent) | 5.90% |  | 7.30% |
Consumer Health | OTC |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,372 | 1,142 | $ 3,854 | 3,639
Percent Change (as a percent) | 20.10% |  | 5.90% |
Consumer Health | OTC | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 686 | 601 | $ 1,960 | 1,917
Percent Change (as a percent) | 14.00% |  | 2.20% |
Consumer Health | OTC | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 686 | 541 | $ 1,894 | 1,722
Percent Change (as a percent) | 26.90% |  | 10.00% |
Consumer Health | Skin Health/Beauty |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,124 | 1,149 | $ 3,457 | 3,273
Percent Change (as a percent) | (2.20%) |  | 5.60% |
Consumer Health | Skin Health/Beauty | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 569 | 572 | $ 1,862 | 1,767
Percent Change (as a percent) | (0.50%) |  | 5.40% |
Consumer Health | Skin Health/Beauty | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 555 | 577 | $ 1,595 | 1,506
Percent Change (as a percent) | (3.80%) |  | 5.90% |
Consumer Health | Oral Care |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 398 | 412 | $ 1,240 | 1,204
Percent Change (as a percent) | (3.30%) |  | 3.00% |
Consumer Health | Oral Care | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 150 | 164 | $ 478 | 510
Percent Change (as a percent) | (8.40%) |  | (6.20%) |
Consumer Health | Oral Care | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 248 | 248 | $ 762 | 694
Percent Change (as a percent) | 0.10% |  | 9.90% |
Consumer Health | Baby Care |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 391 | 393 | $ 1,167 | 1,110
Percent Change (as a percent) | (0.30%) |  | 5.20% |
Consumer Health | Baby Care | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 95 | 91 | $ 288 | 279
Percent Change (as a percent) | 5.20% |  | 3.30% |
Consumer Health | Baby Care | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 296 | 302 | $ 879 | 831
Percent Change (as a percent) | (2.00%) |  | 5.80% |
Consumer Health | Women's Health |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 232 | 230 | $ 684 | 664
Percent Change (as a percent) | 0.80% |  | 3.00% |
Consumer Health | Women's Health | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3 | 3 | $ 9 | 10
Percent Change (as a percent) | 20.10% |  | (5.70%) |
Consumer Health | Women's Health | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 229 | 227 | $ 675 | 654
Percent Change (as a percent) | 0.50% |  | 3.10% |
Consumer Health | Wound Care/Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 182 | 189 | $ 575 | 545
Percent Change (as a percent) | (3.50%) |  | 5.40% |
Consumer Health | Wound Care/Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 122 | 125 | $ 390 | 370
Percent Change (as a percent) | (2.60%) |  | 5.30% |
Consumer Health | Wound Care/Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 61 | 64 | $ 186 | 175
Percent Change (as a percent) | (5.20%) |  | 5.80% |
PHARMACEUTICAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 12,994 | 11,418 | $ 37,792 | 33,304
Percent Change (as a percent) | 13.80% |  | 13.50% |
PHARMACEUTICAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 7,221 | 6,438 | $ 20,536 | 18,619
Percent Change (as a percent) | 12.20% |  | 10.30% |
PHARMACEUTICAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 5,773 | 4,980 | $ 17,256 | 14,685
Percent Change (as a percent) | 15.90% |  | 17.50% |
PHARMACEUTICAL | Immunology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4,250 | 3,789 | $ 12,395 | 10,950
Percent Change (as a percent) | 12.20% |  | 13.20% |
PHARMACEUTICAL | Immunology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,771 | 2,558 | $ 7,932 | 7,330
Percent Change (as a percent) | 8.30% |  | 8.20% |
PHARMACEUTICAL | Immunology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,480 | 1,230 | $ 4,464 | 3,619
Percent Change (as a percent) | 20.30% |  | 23.30% |
PHARMACEUTICAL | Immunology | REMICADE® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 761 | 921 | $ 2,426 | 2,846
Percent Change (as a percent) | (17.40%) |  | (14.80%) |
PHARMACEUTICAL | Immunology | REMICADE® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 480 | 634 | $ 1,508 | 1,852
Percent Change (as a percent) | (24.30%) |  | (18.60%) |
PHARMACEUTICAL | Immunology | REMICADE® | U.S. Exports |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 47 | 78 | $ 197 | 321
Percent Change (as a percent) | (40.20%) |  | (38.70%) |
PHARMACEUTICAL | Immunology | REMICADE® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 234 | 209 | $ 721 | 673
Percent Change (as a percent) | 12.20% |  | 7.10% |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 571 | 592 | $ 1,717 | 1,667
Percent Change (as a percent) | (3.30%) |  | 3.00% |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 295 | 312 | $ 840 | 840
Percent Change (as a percent) | (5.30%) |  | 0.00% |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 276 | 280 | $ 877 | 827
Percent Change (as a percent) | (1.10%) |  | 6.10% |
PHARMACEUTICAL | Immunology | STELARA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,378 | 1,947 | $ 6,800 | 5,463
Percent Change (as a percent) | 22.20% |  | 24.50% |
PHARMACEUTICAL | Immunology | STELARA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,569 | 1,313 | $ 4,396 | 3,668
Percent Change (as a percent) | 19.50% |  | 19.90% |
PHARMACEUTICAL | Immunology | STELARA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 809 | 634 | $ 2,404 | 1,795
Percent Change (as a percent) | 27.70% |  | 33.90% |
PHARMACEUTICAL | Immunology | TREMFYA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 537 | 327 | $ 1,434 | 965
Percent Change (as a percent) | 64.10% |  | 48.50% |
PHARMACEUTICAL | Immunology | TREMFYA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 376 | 222 | $ 975 | 650
Percent Change (as a percent) | 69.70% |  | 50.10% |
PHARMACEUTICAL | Immunology | TREMFYA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 161 | 105 | $ 459 | 316
Percent Change (as a percent) | 52.50% |  | 45.40% |
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3 | 3 | $ 18 | 9
Percent Change (as a percent) | (26.40%) |  | 91.60% |
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3 | 0 | $ 15 | 0
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 0 | 3 | $ 3 | 9
Percent Change (as a percent) |  |  | (68.60%) |
PHARMACEUTICAL | Infectious Diseases |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,389 | 864 | $ 3,424 | 2,662
Percent Change (as a percent) | 60.60% |  | 28.60% |
PHARMACEUTICAL | Infectious Diseases | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 679 | 413 | $ 1,635 | 1,265
Percent Change (as a percent) | 64.30% |  | 29.20% |
PHARMACEUTICAL | Infectious Diseases | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 709 | 451 | $ 1,788 | 1,397
Percent Change (as a percent) | 57.20% |  | 28.00% |
PHARMACEUTICAL | Infectious Diseases | COVID-19 |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 502 | 0 | $ 766 | 0
PHARMACEUTICAL | Infectious Diseases | COVID-19 | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 270 | 0 | 421 | 0
PHARMACEUTICAL | Infectious Diseases | COVID-19 | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 233 | 0 | 346 | 0
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 259 | 236 | $ 764 | 716
Percent Change (as a percent) | 9.60% |  | 6.70% |
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 12 | 11 | $ 31 | 33
Percent Change (as a percent) | 8.40% |  | (4.80%) |
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 247 | 226 | $ 733 | 684
Percent Change (as a percent) | 9.70% |  | 7.20% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 517 | 526 | $ 1,568 | 1,615
Percent Change (as a percent) | (1.70%) |  | (2.90%) |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 380 | 379 | $ 1,128 | 1,154
Percent Change (as a percent) | 0.40% |  | (2.20%) |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 137 | 147 | $ 440 | 461
Percent Change (as a percent) | (7.10%) |  | (4.60%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 110 | 102 | $ 325 | 331
Percent Change (as a percent) | 7.80% |  | (1.80%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 18 | 24 | $ 55 | 79
Percent Change (as a percent) | (26.00%) |  | (29.60%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 93 | 78 | $ 270 | 252
Percent Change (as a percent) | 18.30% |  | 6.90% |
PHARMACEUTICAL | Neuroscience |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,689 | 1,605 | $ 5,218 | 4,850
Percent Change (as a percent) | 5.30% |  | 7.60% |
PHARMACEUTICAL | Neuroscience | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 835 | 759 | $ 2,448 | 2,285
Percent Change (as a percent) | 10.20% |  | 7.20% |
PHARMACEUTICAL | Neuroscience | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 854 | 846 | $ 2,770 | 2,565
Percent Change (as a percent) | 0.80% |  | 8.00% |
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 157 | 149 | $ 489 | 469
Percent Change (as a percent) | 4.50% |  | 4.10% |
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 35 | 43 | $ 117 | 150
Percent Change (as a percent) | (19.50%) |  | (22.10%) |
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 122 | 107 | $ 372 | 319
Percent Change (as a percent) | 14.20% |  | 16.40% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,004 | 926 | $ 2,994 | 2,688
Percent Change (as a percent) | 8.50% |  | 11.40% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 648 | 585 | $ 1,882 | 1,704
Percent Change (as a percent) | 11.00% |  | 10.40% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 355 | 341 | $ 1,111 | 983
Percent Change (as a percent) | 4.30% |  | 13.00% |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 140 | 152 | $ 452 | 475
Percent Change (as a percent) | (8.40%) |  | (4.90%) |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 71 | 70 | $ 210 | 220
Percent Change (as a percent) | 1.30% |  | (4.70%) |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 69 | 81 | $ 242 | 254
Percent Change (as a percent) | (16.70%) |  | (5.10%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 388 | 377 | $ 1,284 | 1,218
Percent Change (as a percent) | 3.10% |  | 5.50% |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 81 | 60 | $ 239 | 210
Percent Change (as a percent) | 34.70% |  | 13.90% |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 307 | 317 | $ 1,045 | 1,008
Percent Change (as a percent) | (2.90%) |  | 3.70% |
PHARMACEUTICAL | Oncology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,665 | 3,129 | $ 10,770 | 8,933
Percent Change (as a percent) | 17.10% |  | 20.60% |
PHARMACEUTICAL | Oncology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,525 | 1,267 | $ 4,364 | 3,623
Percent Change (as a percent) | 20.30% |  | 20.40% |
PHARMACEUTICAL | Oncology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,140 | 1,862 | $ 6,406 | 5,310
Percent Change (as a percent) | 14.90% |  | 20.60% |
PHARMACEUTICAL | Oncology | DARZALEX® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,580 | 1,099 | $ 4,378 | 2,937
Percent Change (as a percent) | 43.70% |  | 49.10% |
PHARMACEUTICAL | Oncology | DARZALEX® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 841 | 585 | $ 2,302 | 1,540
Percent Change (as a percent) | 43.70% |  | 49.50% |
PHARMACEUTICAL | Oncology | DARZALEX® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 739 | 514 | $ 2,076 | 1,397
Percent Change (as a percent) | 43.70% |  | 48.60% |
PHARMACEUTICAL | Oncology | ERLEADA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 344 | 206 | $ 907 | 519
Percent Change (as a percent) | 66.70% |  | 74.70% |
PHARMACEUTICAL | Oncology | ERLEADA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 214 | 152 | $ 578 | 407
Percent Change (as a percent) | 40.50% |  | 41.80% |
PHARMACEUTICAL | Oncology | ERLEADA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 130 | 55 | $ 329 | 112
PHARMACEUTICAL | Oncology | IMBRUVICA® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,066 | 1,031 | $ 3,307 | 3,011
Percent Change (as a percent) | 3.50% |  | 9.90% |
PHARMACEUTICAL | Oncology | IMBRUVICA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 413 | 450 | $ 1,311 | 1,329
Percent Change (as a percent) | (8.30%) |  | (1.30%) |
PHARMACEUTICAL | Oncology | IMBRUVICA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 654 | 581 | $ 1,996 | 1,682
Percent Change (as a percent) | 12.60% |  | 18.70% |
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 548 | 590 | $ 1,749 | 1,848
Percent Change (as a percent) | (7.20%) |  | (5.40%) |
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 25 | 58 | $ 96 | 284
Percent Change (as a percent) | (57.00%) |  | (66.20%) |
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 523 | 532 | $ 1,653 | 1,564
Percent Change (as a percent) | (1.80%) |  | 5.70% |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY(1) |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 126 | 203 | $ 428 | 619
Percent Change (as a percent) | (37.60%) |  | (30.70%) |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY(1) | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 32 | 21 | $ 76 | 63
Percent Change (as a percent) | 49.60% |  | 21.00% |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY(1) | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 94 | 181 | $ 352 | 556
Percent Change (as a percent) | (48.00%) |  | (36.60%) |
PHARMACEUTICAL | Pulmonary Hypertension |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 868 | 749 | $ 2,599 | 2,283
Percent Change (as a percent) | 15.90% |  | 13.90% |
PHARMACEUTICAL | Pulmonary Hypertension | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 610 | 510 | $ 1,778 | 1,541
Percent Change (as a percent) | 19.70% |  | 15.40% |
PHARMACEUTICAL | Pulmonary Hypertension | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 258 | 239 | $ 821 | 742
Percent Change (as a percent) | 7.90% |  | 10.70% |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 458 | 392 | $ 1,371 | 1,187
Percent Change (as a percent) | 17.00% |  | 15.50% |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 299 | 244 | $ 861 | 729
Percent Change (as a percent) | 22.80% |  | 18.20% |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 159 | 148 | $ 510 | 458
Percent Change (as a percent) | 7.40% |  | 11.30% |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 309 | 260 | $ 927 | 792
Percent Change (as a percent) | 19.00% |  | 17.10% |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 265 | 226 | $ 792 | 692
Percent Change (as a percent) | 17.30% |  | 14.60% |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 44 | 34 | $ 135 | 100
Percent Change (as a percent) | 30.40% |  | 34.60% |
PHARMACEUTICAL | Pulmonary Hypertension | Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 101 | 97 | $ 301 | 304
Percent Change (as a percent) | 3.40% |  | (1.10%) |
PHARMACEUTICAL | Pulmonary Hypertension | Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 47 | 40 | $ 125 | 121
Percent Change (as a percent) | 14.40% |  | 2.80% |
PHARMACEUTICAL | Pulmonary Hypertension | Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 54 | 57 | $ 176 | 183
Percent Change (as a percent) | (4.40%) |  | (3.70%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,133 | 1,281 | $ 3,386 | 3,625
Percent Change (as a percent) | (11.50%) |  | (6.60%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 800 | 931 | $ 2,379 | 2,574
Percent Change (as a percent) | (14.00%) |  | (7.60%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 333 | 351 | $ 1,007 | 1,052
Percent Change (as a percent) | (5.10%) |  | (4.20%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 636 | 630 | $ 1,794 | 1,716
Percent Change (as a percent) | 0.80% |  | 4.50% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 636 | 630 | $ 1,794 | 1,716
Percent Change (as a percent) | 0.80% |  | 4.50% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 133 | 224 | $ 443 | 578
Percent Change (as a percent) | (40.30%) |  | (23.40%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 66 | 156 | $ 249 | 405
Percent Change (as a percent) | (57.40%) |  | (38.40%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 67 | 68 | $ 194 | 173
Percent Change (as a percent) | (1.00%) |  | 11.90% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 112 | 132 | $ 366 | 423
Percent Change (as a percent) | (14.60%) |  | (13.40%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 47 | 69 | $ 168 | 215
Percent Change (as a percent) | (30.90%) |  | (21.70%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 65 | 63 | $ 198 | 208
Percent Change (as a percent) | 3.10% |  | (4.70%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 251 | 294 | $ 783 | 908
Percent Change (as a percent) | (14.80%) |  | (13.80%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 51 | 75 | $ 168 | 238
Percent Change (as a percent) | (32.60%) |  | (29.30%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 200 | 219 | $ 615 | 670
Percent Change (as a percent) | (8.70%) |  | (8.30%) |
MEDICAL DEVICES |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 6,644 | 6,150 | $ 20,201 | 16,370
Percent Change (as a percent) | 8.00% |  | 23.40% |
MEDICAL DEVICES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,117 | 3,092 | $ 9,470 | 7,852
Percent Change (as a percent) | 0.80% |  | 20.60% |
MEDICAL DEVICES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,527 | 3,058 | $ 10,731 | 8,518
Percent Change (as a percent) | 15.40% |  | 26.00% |
MEDICAL DEVICES | Interventional Solutions |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 957 | 836 | $ 2,952 | 2,153
Percent Change (as a percent) | 14.50% |  | 37.10% |
MEDICAL DEVICES | Interventional Solutions | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 444 | 399 | $ 1,353 | 1,019
Percent Change (as a percent) | 11.10% |  | 32.70% |
MEDICAL DEVICES | Interventional Solutions | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 513 | 437 | $ 1,599 | 1,134
Percent Change (as a percent) | 17.70% |  | 41.10% |
MEDICAL DEVICES | Orthopaedics |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,093 | 2,083 | $ 6,433 | 5,572
Percent Change (as a percent) | 0.50% |  | 15.40% |
MEDICAL DEVICES | Orthopaedics | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,249 | 1,308 | $ 3,821 | 3,427
Percent Change (as a percent) | (4.50%) |  | 11.50% |
MEDICAL DEVICES | Orthopaedics | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 843 | 774 | $ 2,611 | 2,145
Percent Change (as a percent) | 8.80% |  | 21.70% |
MEDICAL DEVICES | Orthopaedics | HIPS |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 356 | 345 | $ 1,105 | 908
Percent Change (as a percent) | 3.30% |  | 21.80% |
MEDICAL DEVICES | Orthopaedics | HIPS | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 210 | 221 | $ 654 | 564
Percent Change (as a percent) | (5.30%) |  | 15.90% |
MEDICAL DEVICES | Orthopaedics | HIPS | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 146 | 124 | $ 451 | 344
Percent Change (as a percent) | 18.80% |  | 31.30% |
MEDICAL DEVICES | Orthopaedics | KNEES |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 316 | 308 | $ 983 | 825
Percent Change (as a percent) | 2.80% |  | 19.20% |
MEDICAL DEVICES | Orthopaedics | KNEES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 184 | 205 | $ 579 | 527
Percent Change (as a percent) | (9.80%) |  | 10.00% |
MEDICAL DEVICES | Orthopaedics | KNEES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 131 | 102 | $ 403 | 298
Percent Change (as a percent) | 28.10% |  | 35.40% |
MEDICAL DEVICES | Orthopaedics | TRAUMA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 715 | 685 | $ 2,157 | 1,892
Percent Change (as a percent) | 4.20% |  | 14.00% |
MEDICAL DEVICES | Orthopaedics | TRAUMA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 455 | 433 | $ 1,352 | 1,194
Percent Change (as a percent) | 5.30% |  | 13.30% |
MEDICAL DEVICES | Orthopaedics | TRAUMA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 260 | 253 | $ 805 | 698
Percent Change (as a percent) | 2.40% |  | 15.20% |
MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS & OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 705 | 745 | $ 2,187 | 1,947
Percent Change (as a percent) | (5.30%) |  | 12.30% |
MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS & OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 400 | 449 | $ 1,236 | 1,142
Percent Change (as a percent) | (11.10%) |  | 8.20% |
MEDICAL DEVICES | Orthopaedics | SPINE, SPORTS & OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 306 | 295 | $ 952 | 805
Percent Change (as a percent) | 3.50% |  | 18.20% |
MEDICAL DEVICES | Surgery |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,405 | 2,152 | $ 7,299 | 5,803
Percent Change (as a percent) | 11.80% |  | 25.80% |
MEDICAL DEVICES | Surgery | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 948 | 913 | $ 2,881 | 2,247
Percent Change (as a percent) | 3.90% |  | 28.20% |
MEDICAL DEVICES | Surgery | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,457 | 1,239 | $ 4,418 | 3,556
Percent Change (as a percent) | 17.60% |  | 24.20% |
MEDICAL DEVICES | Surgery | ADVANCED |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,144 | 1,000 | $ 3,430 | 2,723
Percent Change (as a percent) | 14.60% |  | 26.00% |
MEDICAL DEVICES | Surgery | ADVANCED | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 440 | 421 | $ 1,304 | 1,079
Percent Change (as a percent) | 4.60% |  | 20.90% |
MEDICAL DEVICES | Surgery | ADVANCED | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 705 | 579 | $ 2,126 | 1,644
Percent Change (as a percent) | 21.80% |  | 29.30% |
MEDICAL DEVICES | Surgery | GENERAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,261 | 1,152 | $ 3,869 | 3,080
Percent Change (as a percent) | 9.40% |  | 25.60% |
MEDICAL DEVICES | Surgery | GENERAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 508 | 492 | $ 1,577 | 1,168
Percent Change (as a percent) | 3.30% |  | 35.00% |
MEDICAL DEVICES | Surgery | GENERAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 752 | 660 | $ 2,292 | 1,912
Percent Change (as a percent) | 13.90% |  | 19.90% |
MEDICAL DEVICES | Vision |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,189 | 1,081 | $ 3,517 | 2,843
Percent Change (as a percent) | 10.10% |  | 23.70% |
MEDICAL DEVICES | Vision | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 475 | 473 | $ 1,414 | 1,160
Percent Change (as a percent) | 0.60% |  | 21.90% |
MEDICAL DEVICES | Vision | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 714 | 608 | $ 2,103 | 1,683
Percent Change (as a percent) | 17.40% |  | 25.00% |
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 882 | 830 | $ 2,607 | 2,198
Percent Change (as a percent) | 6.20% |  | 18.60% |
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 359 | 375 | $ 1,082 | 924
Percent Change (as a percent) | (4.30%) |  | 17.00% |
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 522 | 455 | $ 1,525 | 1,274
Percent Change (as a percent) | 14.90% |  | 19.80% |
MEDICAL DEVICES | Vision | SURGICAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 308 | 251 | $ 910 | 645
Percent Change (as a percent) | 22.70% |  | 41.10% |
MEDICAL DEVICES | Vision | SURGICAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 117 | 98 | $ 333 | 236
Percent Change (as a percent) | 19.60% |  | 41.10% |
MEDICAL DEVICES | Vision | SURGICAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 191 | $ 153 | $ 577 | $ 409
Percent Change (as a percent) | 24.70% |  | 41.10% |

X
- Definition Percentage change in sales by segment of business. + References No definition available. + Details
Name: | jnj_PercentageChangeInSalesBySegmentOfBusiness
Namespace Prefix: | jnj_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_BeautyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OralCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_BabyCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WomensHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_StelaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TremfyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_COVID19Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_DARZALEXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ERLEADAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_IMBRUVICAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ZYTIGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OPSUMITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_UPTRAVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_XareltoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PROCRITEPREXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_HIPSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_KNEESMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TRAUMAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPINEOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ADVANCEDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_GENERALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_VisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SURGICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |